FDA approves combination therapy for higher-risk clear cell kidney cancer after surgery
The U.S. Food and Drug Administration (FDA) has approved pembrolizumab, an immunotherapy, plus belzutifan, a HIF-2α inhibitor, as adjuvant treatment for adult patients with renal cell carcinoma with a clear cell component ...
21 hours ago
0
2








